FABP1 Antibody, FITC conjugated

說明書

中文名稱：

FABP1兔多克隆抗體, FITC偶聯
貨號：

CSB-PA007940YC01HU
規格：

￥880
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) FABP1 Polyclonal antibody
Uniprot No.：

P07148
基因名：

FABP1
別名：

FABP 1 antibody; FABP1 antibody; FABPL antibody; FABPL_HUMAN antibody; Fatty Acid Binding Protein 1 antibody; Fatty acid binding protein 1 liver antibody; Fatty Acid Binding Protein antibody; Fatty acid-binding protein 1 antibody; Fatty acid-binding protein antibody; Fatty acid-binding protein liver antibody; L FABP antibody; L-FABP antibody; liver antibody; Liver-type fatty acid-binding protein antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human Fatty acid-binding protein, liver protein (1-127AA)
免疫原種屬：

Homo sapiens (Human)
標記方式：

FITC
克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產品提供形式：

Liquid
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Plays a role in lipoprotein-mediated cholesterol uptake in hepatocytes. Binds cholesterol. Binds free fatty acids and their coenzyme A derivatives, bilirubin, and some other small molecules in the cytoplasm. May be involved in intracellular lipid transport.
基因功能參考文獻：
1. urinary level associated with the chronic kidney disease classification in HIV-infected patients, but not associated with antiretroviral therapy and tenofovir disoproxil fumarate PMID: 27761670
2. Both peak oxygen consumption and grip strength were inversely associated with urinary L-FABP levels in middle-aged and older individuals without chronic kidney disease. PMID: 28197733
3. Nonrenal conditions and systemic severity should be considered for improved AKI prediction by NGAL and L-FABP as biomarkers. PMID: 27605390
4. urine L-FABP/C is permanently elevated in chronic kidney disease patients. PMID: 28745927
5. Our data suggests that the polymorphism in genes IL-1beta, IL-1Ra and FABP1 included in this study are not associated with PCOS development, but can influence important biochemical and metabolic parameters in PCOS. PMID: 28405733
6. On PICU day 1, interleukin-18 predicted acute kidney injury with area under the curve=0.82, but neutrophil gelatinase-associated lipocalin and liver fatty acid binding protein predicted acute kidney injury with area under the curve of less than or equal to 0.69; on PICU day 2, area under the curve was higher. Interleukin-18 and liver fatty acid binding protein on day 1 predicted prolonged acute kidney injury. PMID: 28430754
7. In total, 68 miRNAs potentially targeting FABP1 were selected; of these, miR-3941, miR-4517, and miR-4672 directly targeted the FABP1 3' untranslated region. Mimics of the three miRNAs substantially repressed FABP1 expression at translational level and led to HepG2 cell resistance to steatosis and cell injury induced by free fatty acids mixture, which rescue of FABP1 overexpression reversed. PMID: 29258109
8. This study demonstrated that the loss of FABP1 expression is associated with MSI carcinomas and that interferon gamma stimulation plays a role in this process via its interaction with PPARgamma. PMID: 27687006
9. Hepatic adenomas co-occurring with fibrolamellar carcinomas show LFABP loss and are negative for PRKACA rearrangements, indicating they are genetically distinct lesions. These data also demonstrate that LFABP loss, which characterizes HNF1-alpha inactivation, is a consistent feature of fibrolamellar carcinoma, indicating HNF1-alpha inactivation is an important event in fibrolamellar carcinoma pathogenesis. PMID: 27015136
10. studies indicate that FABP1 is essential for proper lipid metabolism in differentiated enterocytes, particularly concerning fatty acids uptake and its basolateral secretion. PMID: 28919479
11. CDH5 and FABP1 expression levels were both elevated in drug-induced liver injury. PMID: 27224670
12. A high resolution NMR comparative molecular analysis of L-FABP T94T and L-FABP T94A in their unbound states and in the presence of representative ligands of the fatty acid and bile acid classes showed that threonine to alanine replacement did not result in strongly perturbed structural and dynamic features, although differences in oleic acid binding by the two variants were detected. PMID: 28668637
13. Studies show that despite overall tertiary structure similarity, the hFABP1 differs significantly from rat FABP1 in secondary structure, much larger ligand binding cavity, and affinities/specificities for some ligands. Moreover, while both mouse and hFABP1 mediate ligand induction of PPARA, they differ markedly in genes induced. hFABP1 T94A variant is associated with altered body mass index.[review] PMID: 27117865
14. analysis of structural, dynamic, and binding properties of the liver fatty acid binding protein (LFABP) in crowded solutions PMID: 27457417
15. Urinary L-FABP, NGAL, Kim-1 and albumin levels increased during the acute phase of kidney injury and were significantly correlated with the degree of tubulointerstitial fibrosis during the chronic phase. These markers could detect higher risk of progression to CKD. PMID: 27028054
16. L-FABP was found to associate with VEGFR2 on membrane rafts and subsequently activate the Akt/mTOR/P70S6K/4EBP1 and Src/FAK/cdc42 pathways, which resulted in up-regulation of VEGF-A accompanied by an increase in both angiogenic potential and migration activity. L-FABP significantly promoted tumor growth and metastasis in a xenograft mouse model. PMID: 26919097
17. In chronic kidney disease, high urinary L-FABP correlated with the development of end-stage renal disease and cardiovascular disease. PMID: 26189083
18. In the association of SNPs in FABP1 gene with PCOS, rs2197076 was more closely associated with its main features than rs2241883 and seemed to play a more important role in the pathogenesis of PCOS. PMID: 26650609
19. Report interaction of perfluoroalkyl acids with human liver fatty acid-binding protein. PMID: 25370009
20. Urinary L-FABP appears to be a sensitive biomarker of acute kidney injury in patients undergoing abdominal aortic repair. PMID: 26585768
21. Urinary levels of NGAL are more sensitive than uKIM-1 and uL-FABP levels in predicting renal scarring in vesicoureteral reflux. PMID: 26324091
22. Loss of staining for LFABP appears to be common in hepatocellular carcinoma and may be seen in well-differentiated hepatocellular carcinoma. PMID: 26997447
23. In this study, the effects of hepatitis B virus X protein (HBx) mediated FABP1 regulation on hepatic steatosis and the underlying mechanism were determined. PMID: 26637457
24. compared with the rs2919872 G allele, the rs2919872 A allele reduces the transcriptional activity of FABP1 promoter, and thereby may link FABP1 gene variation to triglyceride level in humans. PMID: 26439934
25. Higher urinary L-FABP was found in pregnant with and without gestational diabetes mellitus(GDM), and considerably higher urinary L-FABP was found in the GDM group compared with the non-GDM group. PMID: 26254248
26. Multivariable regression analysis revealed that urinary L-FABP and urinary albumin/ creatinine ratio were significantly associated with urinary ACE2 levels. PMID: 26067610
27. Measurement of uL-FABP levels at 48 h after coronary angiography may be useful in detecting renal damage, and in predicting 1-year renal outcome in ischemic heart disease patients undergoing CAG. PMID: 24554034
28. Measurement of urinary L-FABP and albumin/creatinine ratio should be useful to assess cardiovascular damage reflecting the elevation of cardiac markers and ECG abnormalities in T2DM with CKD. PMID: 24626813
29. Urinary L-FABP is strongly associated with anemia in non-diabetic patients. PMID: 26010898
30. L-FABP is a novel biomarker of diverse kidney diseases. (Review) PMID: 25797895
31. I-FABP and L-FABP are early markers for abdominal injury with limited prognostic value for secondary organ failures in the post-traumatic course PMID: 25324448
32. Both the MTP I128T and the L-FABP T94A polymorphisms can affect serum lipid levels in the Chinese population. PMID: 25663234
33. The study investigates the interaction of L-FAB with phospholipid liposomes. PMID: 25198387
34. The human FABP1 T94A variant protein had 3-fold higher cholesterol-binding affinity than the WT FABP1. PMID: 25732850
35. In smaller HCC, L-FABP downregulation probably occurs because of phenotypic changes during tumor progression. Moreover, this downregulation correlated with tumor differentiation and intratumoral inflammation. PMID: 25516669
36. FABP1 and FABP2 have roles in differentially modulating the activation of PPARalpha in a ligand-selective manner PMID: 25847235
37. Maternal serum LFABP level appears to be correlated with the severity of the preeclampsia and can be used to confirm the diagnosis. PMID: 25399315
38. Data suggest that up-regulation of urinary levels of LFABP, KIM1 (kidney injury molecule 1), and NGAL (neutrophil gelatinase associated lipocalin) can be used as biomarkers to reflect tubular dysfunction in early-stage type 2 diabetic nephropathy. PMID: 24687388
39. There is not a significant association between the FABP1 polymorphisms and aspirin-exacerbated respiratory disease(AERD). PMID: 25338211
40. Urinary L-FABP was an accurate predictor of early renal allograft function. PMID: 25027586
41. Increased serum L-FABP levels are associated with delayed graft function. PMID: 24750195
42. Baseline urinary L-FABP levels can be a predictor for occurrence of contrast-induced kidney disease. PMID: 23604313
43. L-FABP was downregulated in hepatocellular carcinoma and was associated with poor prognosis. PMID: 25436304
44. It has investigated the interaction between human L-FABP and the soluble domain of Plasmodium falciparum UIS3 by NMR spectroscopy. PMID: 23169100
45. NGAL, IL-18, KIM-1, L-FABP, and albumin differed between etiologies and were significantly higher in patients adjudicated with acute kidney injury. PMID: 24375576
46. Human FABP1 T94A variant impacts fatty acid metabolism and PPAR-alpha activation in cultured human female hepatocytes. PMID: 24875102
47. although the T94A substitution did not alter the affinity of human L-FABP for long chain fatty acids, it significantly altered human L-FABP structure and stability PMID: 24628888
48. Data suggest that an SNP in FABP1 (T94A) does not alter affinity of FABP1 for PPARalpha agonists (fibrates); this SNP does alter FABP1 secondary structure, stability, and functional response to fibrates (gene expression up-regulation in hepatocytes). PMID: 24299557
49. L-FABP was not significantly associated with acute kidney injury in adults or children after adjusting for other kidney injury biomarkers (neutrophil gelatinase-associated lipocalin and IL-18). PMID: 23599408
50. MS and NMR were used to study the ligand binding of human liver fatty acid binding protein. Results are consistent for 2 binding sites with different affinity; results indicate a higher affinity for oleate relative to palmitate at each binding site. PMID: 23893635
顯示更多

收起更多
亞細胞定位：

Cytoplasm.
蛋白家族：

Calycin superfamily, Fatty-acid binding protein (FABP) family
數據庫鏈接：

HGNC: 3555

OMIM: 134650

KEGG: hsa:2168

STRING: 9606.ENSP00000295834

UniGene: Hs.380135

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human